Free Trial
NASDAQ:TPST

Tempest Therapeutics Q3 2026 Earnings Results & Report

Tempest Therapeutics logo
$0.34 -0.04 (-10.50%)
Closing price 04:00 PM Eastern
Extended Trading
$0.35 +0.01 (+2.98%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tempest Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.21 versus the -$0.32 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Tempest Therapeutics EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Tempest Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tempest Therapeutics Q3 2026 Earnings FAQ

Tempest Therapeutics (NASDAQ:TPST) reported earnings of -$0.21 per share for Q3 2026, beating the consensus estimate of -$0.32. The report was announced on Friday, November 13, 2026.

Tempest Therapeutics Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Tempest Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tempest Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tempest Therapeutics and other key companies, straight to your email.

About Tempest Therapeutics

Tempest Therapeutics (NASDAQ:TPST) is a clinical-stage biotechnology company focused on developing treatments for cancer. The company’s research centers on small-molecule medicines designed to affect biological pathways involved in tumor growth and the immune response.

Its lead candidate, TPST-1120, is an oral inhibitor of PPARα that has been studied for advanced liver cancer, including in combination with other cancer therapies. Tempest has also worked on additional drug candidates targeting immune-related pathways.

Based in South San Francisco, California, Tempest conducts drug development rather than marketing approved products. Its work is primarily focused on oncology research and clinical development.

View Tempest Therapeutics Profile